PATER	MAR 1 4 2008	ork Redu	ction Act of 1995, no persons	PTO/SB/08A (01-08) Approved for use through 03/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE is are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitut	e for form 1449A/PT()			Complete if Known	
				Application Number	10/580,761	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	May 25, 2006	
				First Named Inventor	Curtis Dobson	
				Art Unit	1648	
(Use as many sheets as necessary)				Examiner Name	Jeffrey S. Parkin	
Sheet	1	of	2	Attorney Docket Number	81599-3	

MAR 1 4 2008

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear	
		US-				
_		US-				
		US-				
		US-	, .			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-	<u> </u>			
		US-				
		US-				
		US-				
		US-	•			
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document		
	1	WO94/04177	03-03-1994	The Rogosin Institute		

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.qov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B(01-08)

Approved for use through 03/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/580,761 INFORMATION DISCLOSURE Filing Date May 25, 2006 STATEMENT BY APPLICANT First Named Inventor **Curtis Dobson** Art Unit 1648 (Use as many sheets as necessary) Examiner Name Jeffrey S. Parkin Sheet of 81599-3 Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1				
	1	Azuma et al., A Synthetic Peptide Of Human Apoprotein E With Antibacterial Activity, Peptides, (2000), pp. 327-330, 21.			
	2	Clay et al., Localization Of A Domain In Apolipoprotein E With Both Cytostatic And Cytotoxic Activity, Biochemistry, (1995), pp. 11142-11151, 34.			
	3	Owens et al., Apolipoprotein A-I And Its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation, Journal of Clinical Investigations, (October 1990), pp. 1142-1150, 86.			
	4	Srinivas et al., Inhibition Of Virus-Induced Cell Fusion By Apolipoprotein A-I and Its Amphipathic Peptide Analogs, Journal Of Cellular Biochemistry, (1991), pp. 224-237, 45.			

Examiner Signature	Date Considered	
Olgitature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.